Page 17 - 《中国药房》2025年11期

[26] 贾思侬，谢丽，李磊，等. 液体活检技术应用于肿瘤筛检 41（Supp. 16）：1078.
的研究现状[J]. 中国肿瘤，2019，28（10）：774-779. [38] HU X，ZHANG Q，SUN T，et al. LBA5 Capivasertib （C） +
[27] 辇伟奇，于津浦，袁响林，等 . ctDNA 高通量测序临床实 fulvestrant （F） for patients （pts） with aromatase inhibitor
践专家共识：2022 年版[J]. 中国癌症防治杂志，2022，14 （AI）-resistant HR+/HER2-advanced breast cancer（ABC）：
（3）：240-252. phase Ⅲ CAPItello-291 trial Chinese cohort[J]. Ann
[28] IWATA H，MASUDA N，YAMAMOTO D，et al. Circula- Oncol，2023，34：S1485-S1486.
ting tumor cells as a prognostic marker for efficacy in the [39] TURNER N C，IM S A，SAURA C，et al. Inavolisib-based
randomized phase Ⅲ JO21095 trial in Japanese patients therapy in PIK3CA-mutated advanced breast cancer[J]. N
with HER2-negative metastatic breast cancer[J]. Breast Engl J Med，2024，391（17）：1584-1596.
Cancer Res Treat，2017，162（3）：501-510. [40] TURNER N C，OLIVEIRA M，HOWELL S J，et al.
[29] SHIOMI-MOURI Y，KOUSAKA J，ANDO T，et al. Clini‐ Capivasertib in hormone receptor-positive advanced breast
cal significance of circulating tumor cells （CTCs） with re‐ cancer[J]. N Engl J Med，2023，388（22）：2058-2070.
spect to optimal cut-off value and tumor markers in ad‐ [41] YARDLEY D A，NOGUCHI S，PRITCHARD K I，et al.
vanced/metastatic breast cancer[J]. Breast Cancer，2016， Everolimus plus exemestane in postmenopausal patients
23（1）：120-127. with HR（+） breast cancer：BOLERO-2 final progression-
[30] ROSSI G，MU Z M，RADEMAKER A W，et al. Cell-free free survival analysis[J]. Adv Ther，2013，30（10）：
DNA and circulating tumor cells：comprehensive liquid 870-884.
biopsy analysis in advanced breast cancer[J]. Clin Cancer [42] KORNBLUM N，ZHAO F M，MANOLA J，et al. Ran‐
Res，2018，24（3）：560-568. domized phase Ⅱ trial of fulvestrant plus everolimus or
[31] 中华医学会检验医学分会分子诊断学组.循环肿瘤细胞 placebo in postmenopausal women with hormone
临床应用与实验室检测专家共识[J]. 中华检验医学杂 receptor-positive，human epidermal growth factor receptor
志，2021，44（11）：1008-1020. 2-negative metastatic breast cancer resistant to aromatase
[32] Novartis Pharmaceuticals Corporation. Highlights of pre‐ inhibitor therapy：results of PrE0102[J]. J Clin Oncol，
scribing information，PIQRAY （Alpelisib） tablets，for 2018，36（16）：1556-1563.
®
oral use，Initial U.S.[EB/OL]. [2024-11-10]. https：//www. [43] 国家卫生健康委办公厅. 国家卫生健康委办公厅关于印
accessdata. fda. gov/drugsatfda_docs/label/2024/212526s- 发新型抗肿瘤药物临床应用指导原则（2023 年版）的通
009lbl.pdf. 知[EB/OL].（2024-01-02）[2024-11-04]. https：//www.gov.
[33] Genentech，Inc. Highlights of prescribing information， cn/zhengce/zhengceku/202401/content_6925043.htm.
ITOVEBI （inavolisib） tablets，for oral use，Initial U. S. [44] CIRUELOS E M，LOIBL S，CAMPONE M，et al. Clinical
[EB/OL]. [2024-11-10]. https：//www.accessdata.fda.gov/ outcome of alpelisib plus fulvestrant in hormone receptor-
drugsatfda_docs/label/2024/219249s000lbl.pdf. positive，human epidermal growth factor receptor 2-nega‐
[34] AstraZeneca Pharmaceuticals LP. Highlights of prescri- tive advanced breast cancer with PIK3CA alterations de‐
bing information，TRUQAP （capivasertib） tablets，for tected in plasma ctDNA by next-generation sequencing：
®
oral use，Initial U.S.[EB/OL]. [2024-11-10]. https：//www. biomarker analysis from the SOLAR-1 study[EB/OL].
accessdata. fda. gov/drugsatfda_docs/label/2023/218197s- （2019-07-01）[2024-11-10]. https：//aacrjournals. org/can‐
000lbl.pdf. cerres/article/81/4_Supplement/PD2-06/647940/Abstract-
[35] Novartis Pharmaceuticals Corporation. Highlights of pre‐ PD2-06-Clinical-outcomes-of-alpelisib．
scribing information，AFINITOR （everolimus） tablets， [45] RUGO H S，SCHROCK A B，RASKINA K，et al. Real-
®
for oral administration，AFINITOR DISPERZ （everoli‐ world （RW） clinical outcomes on alpelisib （ALP） in pa‐
®
mus tablets for oral suspension），Initial U. S. [EB/OL]. tients （pts） with breast cancer （BC） and PIK3CA muta‐
[2024-11-10]. https：//www.accessdata.fda.gov/drugsatfda_ tions （PIK3CAm）[EB/OL]. （2021-06-04）[2024-11-10].
docs/label/2022/203985s023,022334s051lbl.pdf. https：//ascopubs. org/doi/10.1200/JCO. 2021.39.15_suppl.
[36] NIH. Study assessing the efficacy and safety of alpelisib 1068．
plus fulvestrant or letrozole，based on prior endocrine [46] KALINSKY K，HONG F，MCCOURT C K，et al. Effect
therapy，in patients with PIK3CA mutant，HR+ ，HER2- of capivasertib in patients with an AKT1 E17K-mutated
advanced breast cancer who have progressed on or after tumor：NCI-MATCH subprotocol EAY131-Y nonrando-
prior treatments （BYLieve）[EB/OL].[2024-11-10].https：// mized trial[J]. JAMA Oncol，2021，7（2）：271-278.
clinicaltrials.gov/study/NCT03056755?tab=results. [47] MARBURY T，EL-HASHIMY M，BLUMENSTEIN L，
[37] CHIA S，NEVEN P，CIRUELOS E M，et al. Alpelisib + et al. Pharmacokinetics and safety of multiple-dose al‐
endocrine therapy in patients with PIK3CA-mutated，hor‐ pelisib in participants with moderate or severe hepatic im‐
mone receptor-positive，human epidermal growth factor pairment：a phase 1，open-label，parallel group study[J]. J
receptor 2-negative，advanced breast cancer：analysis of Cancer，2023，14（9）：1571-1578.
all 3 cohorts of the BYLieve study[J]. J Clin Oncol，2023， [48] KOVARIK J M，SABIA H D，FIGUEIREDO J，et al. In‐

中国药房 2025年第36卷第11期 China Pharmacy 2025 Vol. 36 No. 11 · 1299 ·